The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia

The mortality and response rate after FLANG regimen in patients with refractory/relapsed acute leukemia

Background: Oncologists today are greatly concerned about the treatment of relapsed/refractory acute leukemia. FLANG regimen, combination of novantron, cytarabine, fludarabine, and granulocyte-colony stimulating factor, has been used in treatment of refractory/relapsed acute leukemia since 1990s. Th...

Full description

Bibliographic Details
Main Authors: Vali A Mehrzad, Lida Liaghat, Farzaneh Ashrafi, Mehdi Tazhibi, Mehri Hajalikhani, Neda Alijanian
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2012-01-01
Series:Advanced Biomedical Research
Subjects:
Bone marrow transplantation
FLANG regimen
Refractory acute leukemia
Relapsed acute leukemia
Online Access:http://www.advbiores.net/article.asp?issn=2277-9175;year=2012;volume=1;issue=1;spage=54;epage=54;aulast=Mehrzad

Internet

http://www.advbiores.net/article.asp?issn=2277-9175;year=2012;volume=1;issue=1;spage=54;epage=54;aulast=Mehrzad

Similar Items